BRPI0412354A - formulação com liberação prolongada para cloridrato de venlafaxina - Google Patents
formulação com liberação prolongada para cloridrato de venlafaxinaInfo
- Publication number
- BRPI0412354A BRPI0412354A BRPI0412354-9A BRPI0412354A BRPI0412354A BR PI0412354 A BRPI0412354 A BR PI0412354A BR PI0412354 A BRPI0412354 A BR PI0412354A BR PI0412354 A BRPI0412354 A BR PI0412354A
- Authority
- BR
- Brazil
- Prior art keywords
- drug
- formulation
- functional
- drug substance
- sustained release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"FORMULAçãO COM LIBERAçãO PROLONGADA PARA CLORIDRATO DE VENLAFAXINA". A presente invenção refere-se a uma composição com liberação prolongada que: (1) não apresenta a maior distribuição inicial de fármaco que ocorre em sistemas com liberação prolongada que contêm o fármaco solúvel em água cloridrato de venlafaxina, conhecida como fenómeno de explosão, usando um núcleo funcional parcial ou totalmente revestido com uma camada ou película de revestimento funcional; (2) distribui a substância farmacológica dentro de 24 horas e é, portanto, apropriada para administração uma vez ao dia da dita substância farmacológica; (3) apresenta linearidade entre a potência da forma de dosagem e a massa total da forma de dosagem, pelo aumento proporcional das quantidades da substância farmacológica e dos excipientes na formulação; (4) pode ser dividida em doses menores, sem afetar a liberação da substância farmacológica. A invenção fornece uma formulação de cápsula com liberação prolongada, que contém um número apropriado de minicomprimidos complexos funcionais que compreendem: (1) um núcleo funcional que compreende o ingrediente ativo, especialmente o fármaco solúvel em água, cloridrato de venlafaxina, e excipientes apropriados; (2) uma camada ou película de revestimento funcional que reduz a superfície inicial do núcleo, disponível para a liberação do fármaco solúvel em água cloridrato de venlafaxina, evitando o fenómeno de 'explosão'.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03386019A EP1502587B1 (en) | 2003-07-30 | 2003-07-30 | Sustained release formulation for Venlafaxine hydrochloride |
PCT/GR2004/000039 WO2005009414A1 (en) | 2003-07-30 | 2004-07-23 | Sutained release formulation for venlafaxine hydrochloride |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0412354A true BRPI0412354A (pt) | 2006-09-05 |
Family
ID=33522496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0412354-9A BRPI0412354A (pt) | 2003-07-30 | 2004-07-23 | formulação com liberação prolongada para cloridrato de venlafaxina |
Country Status (15)
Country | Link |
---|---|
US (2) | US20060182797A1 (pt) |
EP (1) | EP1502587B1 (pt) |
AT (1) | ATE336988T1 (pt) |
AU (1) | AU2004258732B2 (pt) |
BR (1) | BRPI0412354A (pt) |
CA (1) | CA2529393C (pt) |
CY (1) | CY1107576T1 (pt) |
DE (1) | DE60307819T2 (pt) |
DK (1) | DK1502587T3 (pt) |
ES (1) | ES2271514T3 (pt) |
PL (1) | PL207998B1 (pt) |
PT (1) | PT1502587E (pt) |
SI (1) | SI1502587T1 (pt) |
WO (1) | WO2005009414A1 (pt) |
ZA (1) | ZA200600790B (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL146462A (en) | 2001-11-13 | 2015-02-26 | Lycored Bio Ltd | Prolonged-release preparations containing as an active compound and analapaxin hydrochloride |
EP1572160A2 (en) * | 2002-11-28 | 2005-09-14 | Themis Laboratories Private Limited | Process for manufacturing sustained release microbeads containing venlafaxine hci |
WO2005048979A2 (en) * | 2003-10-06 | 2005-06-02 | Torrent Pharmaceuticals Limited | Pharmaceutical composition having casing with multiple micro tablets |
DK1711169T3 (da) * | 2004-02-04 | 2007-09-17 | Alembic Ltd | Coatede mikrodepottabletter med venlafaxinhydrochlorid |
WO2006136927A1 (en) * | 2005-06-22 | 2006-12-28 | Glenmark Pharmaceuticals Limited | Extended release formulations comprising venlafaxine |
WO2007036952A2 (en) * | 2005-07-01 | 2007-04-05 | Rubicon Research Pvt Ltd. | Novel sustained release dosage form |
US7427414B2 (en) * | 2006-01-18 | 2008-09-23 | Astron Research Limited | Modified release oral dosage form using co-polymer of polyvinyl acetate |
US20090175934A1 (en) * | 2006-03-08 | 2009-07-09 | Jubilant Organosys Ltd. | Extended Release Pharmaceutical Formulation of Venlafaxine and Method of Manufacturing the Same |
WO2007112574A1 (en) * | 2006-04-03 | 2007-10-11 | Isa Odidi | Extended release composition of venlafaxine |
CA2648495C (en) | 2006-04-26 | 2016-07-05 | Alphapharm Pty Ltd | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix |
WO2008140461A1 (en) * | 2007-05-16 | 2008-11-20 | Fmc Corporation | Solid form |
EP2211847A4 (en) * | 2007-10-16 | 2013-10-02 | Alphapharm Pty Ltd | PHARMACEUTICAL FORMULATION WITH CONTROLLED RELEASE |
WO2010100657A2 (en) * | 2009-03-04 | 2010-09-10 | Fdc Limited | A novel oral controlled release dosage forms for water soluble drugs |
US20130004563A1 (en) * | 2011-06-07 | 2013-01-03 | Shah Syed | Multiparticulate s-adenosylmethionine compositions and related methods |
CN103948557A (zh) * | 2014-04-08 | 2014-07-30 | 闻晓光 | 一种新型控释片 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274171B1 (en) * | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
PE57198A1 (es) | 1996-03-25 | 1998-10-10 | American Home Prod | Formula de liberacion prolongada |
UA77145C2 (en) * | 1997-11-05 | 2006-11-15 | Wyeth Corp | Extended release dosage formulation |
CA2698347A1 (en) | 1999-05-20 | 2000-11-30 | Elan Pharma International Limited | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations |
BR0100334A (pt) | 2001-01-17 | 2002-09-24 | Diffucap Chemobras Quimica E F | Processo para a preparação de composições de liberação programada contendo venlafaxina e o produto resultante |
EP1385486A4 (en) * | 2001-04-18 | 2006-05-17 | Nostrum Pharmaceuticals Inc | NEW COATING OF SLOW RELEASE PHARMACEUTICAL COMPOSITION |
CA2457385A1 (en) * | 2001-08-06 | 2003-02-20 | Dr. Reddy's Laboratories Ltd. | Improved enteric formulation of fluoxetin |
US6696496B2 (en) * | 2002-03-28 | 2004-02-24 | Synthon Bv | Low water-soluble venlafaxine salts |
-
2003
- 2003-07-30 AT AT03386019T patent/ATE336988T1/de active
- 2003-07-30 SI SI200330541T patent/SI1502587T1/sl unknown
- 2003-07-30 PT PT03386019T patent/PT1502587E/pt unknown
- 2003-07-30 DE DE60307819T patent/DE60307819T2/de not_active Expired - Lifetime
- 2003-07-30 ES ES03386019T patent/ES2271514T3/es not_active Expired - Lifetime
- 2003-07-30 EP EP03386019A patent/EP1502587B1/en not_active Expired - Lifetime
- 2003-07-30 DK DK03386019T patent/DK1502587T3/da active
-
2004
- 2004-07-23 US US10/565,322 patent/US20060182797A1/en not_active Abandoned
- 2004-07-23 WO PCT/GR2004/000039 patent/WO2005009414A1/en active Application Filing
- 2004-07-23 PL PL379465A patent/PL207998B1/pl not_active IP Right Cessation
- 2004-07-23 CA CA2529393A patent/CA2529393C/en not_active Expired - Fee Related
- 2004-07-23 BR BRPI0412354-9A patent/BRPI0412354A/pt not_active IP Right Cessation
- 2004-07-23 AU AU2004258732A patent/AU2004258732B2/en not_active Ceased
-
2006
- 2006-01-27 ZA ZA200600790A patent/ZA200600790B/en unknown
- 2006-11-10 CY CY20061101625T patent/CY1107576T1/el unknown
-
2011
- 2011-03-23 US US13/069,795 patent/US20110171297A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE336988T1 (de) | 2006-09-15 |
AU2004258732A1 (en) | 2005-02-03 |
PL379465A1 (pl) | 2006-09-18 |
CA2529393A1 (en) | 2005-02-03 |
EP1502587B1 (en) | 2006-08-23 |
WO2005009414A1 (en) | 2005-02-03 |
CA2529393C (en) | 2010-08-17 |
DK1502587T3 (da) | 2007-01-02 |
ZA200600790B (en) | 2007-04-25 |
ES2271514T3 (es) | 2007-04-16 |
DE60307819D1 (de) | 2006-10-05 |
DE60307819T2 (de) | 2007-10-04 |
SI1502587T1 (sl) | 2007-02-28 |
US20060182797A1 (en) | 2006-08-17 |
CY1107576T1 (el) | 2013-03-13 |
PT1502587E (pt) | 2007-01-31 |
AU2004258732B2 (en) | 2009-06-11 |
EP1502587A1 (en) | 2005-02-02 |
PL207998B1 (pl) | 2011-02-28 |
US20110171297A1 (en) | 2011-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107576T1 (el) | Ταχεια αποδεσμευση των υδατοδιαλυτων φαρμακευτικων ουσιων | |
AP1748A (en) | Chronotherapeutic dosage forms. | |
HUP0203451A2 (hu) | Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra | |
WO2004026262A3 (en) | Abuse-resistant pharmaceutical compositions | |
WO2007103557A3 (en) | Coating capsules with active pharmaceutical ingredients | |
HRP20040323C1 (hr) | Oralni oblici davanja propiverina ili njegovih farmaceutski prihvatljivih soli s produljenim oslobađanjem djelotvone supstance | |
EA200600598A1 (ru) | Лекарственные формы замедленного высвобождения | |
WO2004012699A3 (en) | Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent | |
AU5680100A (en) | Controlled release and taste masking oral pharmaceutical compositions | |
WO2002028376A3 (en) | Chrono delivery formulations and method of use thereof | |
WO2006056711A3 (fr) | Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire | |
NZ594618A (en) | Transdermal pharmaceutical preparations | |
UY24288A1 (es) | Procedimiento para la preparación de una composición de liberación retardada de paroxetina | |
WO2005027843A3 (en) | Chronotherapeutic dosage forms | |
EP2397122A3 (en) | Formulations of neramexane dosage forms | |
WO2007146293A3 (en) | Improved composition and method for taste masking | |
ATE549015T1 (de) | Pharmazeutische wirkstoffhaltige formulierung mit überzug | |
WO2006053089A3 (en) | Methods and formulations for making pharmaceutical compositions containing bupropion | |
MY136136A (en) | Pharmaceutical compositions containing terbinafin and use thereof | |
IL154731A0 (en) | Ion-strength independent sustained release pharmaceutical formulation | |
ES2185452A1 (es) | Composicion farmaceutica de fluoxetina en comprimido dispersable recubierto y su proceso de fabricacion. | |
WO2001013898A3 (en) | Pharmaceutical formulations with different release times | |
WO2005115346A3 (en) | Pharmaceutical composition containing risperidone | |
IL179177A (en) | A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product | |
WO2002062299A3 (en) | Improved controlled release oral dosage form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA: INT. CL. A61K 9/48, 31/137; A61P 25/24 Ipc: A61K 9/48 (2011.01), A61K 31/137 (2011.01), A61P 2 |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2264 DE 27/05/2014. |